I
ntravenous alteplase was approved by the Food and Drug Administration for treatment of acute ischemic stroke in 1996 based on the 2 pivotal NINDS trials (National Institute of Neurologic Diseases and Stroke) showing improved functional outcomes among alteplase-treated patients compared with placebo. 1 A cost-effectiveness analysis performed in 1997 found that for every 1000 theoretical ischemic stroke patients treated with alteplase, 564 quality-adjusted life years and over $4 million US dollars were saved over the course of their lifetimes. 2 This cost-effectiveness analysis was recently confirmed by Boudreau et al. 3 Recognizing that alteplase-treated patients were sicker, had higher pharmacy costs, and required longer intensive care unit stays than patients who did not receive alteplase, the Center for Medicare and Medicaid Services (CMS; the US governmental agency that sets reimbursement rates for Medicare patients) increased the hospital reimbursement in the fiscal year (FY) 2006 for ischemic stroke patients receiving alteplase (diagnosis related group [DRG] 559). The DRG structure was also fundamentally changed in 2008 to severity-based DRGs, allowing for higher reimbursement for patients with complications, but retaining a separate and higher reimbursement DRGs for patients treated with alteplase (DRGs 61-63).
Based on anecdotal evidence that the cost of alteplase had substantially increased over the past several years, we sought to investigate the temporal trends in the manufacturer's sales price of alteplase and compare this to changes in DRG base payments to acute care hospitals.
Methods
Using publicly available information on the CMS website (www.cms. gov), we obtained CMS quarterly payment amounts from January 1, 2005, to October 1, 2014, for alteplase, listed as alteplase recombinant, per mg. CMS payment amounts were converted to the manufacturer's average sales price (ASP) by subtracting 6% cms.gov), which multiplies claims charge data for a given DRG by a single national average cost-to-charge ratio (department-specific), derived from hospital cost reports. The consumer price index was also queried for all prescription drugs, urban areas, during the same study period as reference.
Results
The average sales price for alteplase increased significantly during the study period ( Figure) . The alteplase dose for a typical stroke patient requires a 100 mg vial, the cost of which increased by 111% from 
Discussion
We found that the cost of alteplase has more than doubled over the past decade, whereas prescription drug costs have increased by 30% over the same time frame. Despite this dramatic increase in the cost of this proven effective drug, the reimbursement to hospitals by CMS has increased by only 8%. As a result, the drug cost of alteplase is consuming a substantially larger proportion of the acute care reimbursement to hospitals by CMS. With more than half of the hospital's base payment reimbursement now being directed to lytic drug cost, it may be substantially more difficult now for hospitals to recoup their overall patient care costs.
Potential drivers of the temporal trend of increase in the cost of alteplase include implementation of the higher DRG reimbursement rate to hospitals by CMS, changes in pharmaceutical marketing strategy, and general inflation in healthcare spending. Based on the comparison of the rise in alteplase cost to the consumer price index, we found that general healthcare inflation only accounts for a small proportion of this increase. Implementation of the higher DRG reimbursement did not immediately stimulate an increase in the ASP of alteplase, but a delayed response may have occurred. The acquisition of the company that makes alteplase appeared temporally associated with the steeper price increase that began in 2009; however, we cannot ascertain whether this is a causal or purely coincidental association. Biological drug agents are more challenging to manufacture than classic pharmaceuticals, creating barriers to generic entry even after expiration of initial patents. Some of the original patents for alteplase expired in 2005 to 2006, but there remains an effective monopoly related to later manufacturing technique patents and difficulty of production. 4 While alteplase has been repeatedly shown to be cost-effective in the United States and other countries, some even after the increased costs, 5, 6 cost-effectiveness analyses are typically performed from the societal point of view. Yet the current US healthcare system's reimbursement structures are sharply divided between inpatient and out-of-hospital care. As such, while treatments may be cost-effective over a patient's lifetime because of savings in postacute care, hospitals caring for acute stroke patients may not be appropriately reimbursed or incentivized to make efficacious and cost-effective treatments a priority. Clearly, reimbursement to US acute care hospitals is not keeping up with the sharply rising cost of alteplase. In the long term, this could undermine the recent gains that our organization of care with the creation of stroke centers have made in improving the access of patients to alteplase therapy. 7 However, the reimbursement to hospitals from CMS is supposed to account for the costs of medications and procedures. Each year, CMS calibrates the reimbursement for each DRG based on the charges they receive from hospitals. One possible explanations for why the CMS reimbursement is not keeping pace with the cost of alteplase is the concept of charge compression. Charge compression is a term used to describe the phenomenon that charge markups are more likely in less expensive items than in more expensive items. In pharmaceutical charges, cheaper drugs are typically marked up much more than expensive medications. CMS, however, applies a constant cost:charge ratio to all of the drug charges, meaning that higher cost medications are reimbursed at a lower rate. We note that to receive a reimbursement from CMS that would cover the true cost of alteplase, hospitals would have to markup the charge of alteplase to over $33 000 per dose, a charge that is not reasonable nor feasible. In addition, CMS is reimbursing less to all hospitals for all DRGs as a way to cut costs, which will further reduce the operating margin of hospitals. There are several limitations to our analysis. This analysis only applies to reimbursement for patients within the MEDPAR database, which excludes most patients <65 years and some medicare Health Maintenance Organization patients. The manufacturer's average sales price (as calculated from the listed CMS payment amount) is a national average; the actual price for individual hospitals will vary around this average. Similarly, the DRG base payment amount is only one contributor to the final amount received by an individual hospital for a Medicare patient; the formula for calculating the full DRG payment takes into account several additional local factors, including (but not limited to) a geographic wage index, adjustments for indigent care, medical education, and incentives/ penalties for quality of care. Finally, private insurers may pay more or less than the DRG rates set by CMS, although they typically base their payment amounts on CMS rates.
In summary, the cost of alteplase has increased substantially over the past decade without a proportional increase in CMS DRG reimbursements to acute care hospitals. Medical personnel caring for acute ischemic stroke patients should be aware of these market changes to accurately interpret costeffectiveness analyses, as well as to inform their interactions with acute care hospital administrations and pharmacies regarding costs of acute stroke care at their institutions.
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